Yes, you can select non-MDR1 drugs when indicating your drug priorities, but the final report will also include all drugs.
Please follow these steps to prepare the box and ship the sample to our lab. (Click to read more)
We would suggest you submit another FNA and blood samples to us WHEN the patient's lymphoma relapses. Relapse of lymphoma means that the cancer develops a resistance to certain chemo drugs in use. When this happens, the relapsed cancer cells are usually different from the ones investigated in the naive status, which led to different drug response predictions to the tested drugs. Therefore, it would be better to get new tumor samples and find out what are the new preferred drugs and which of the used drugs still remain effective or became resistant for the relapsed lymphoma. However, the best scenario is to maintain clinical remission for as long a period of time so that you don’t have to order another service from us! If a second service is needed, we offer a 50% discount for returning patients.
We usually send you an email asking for patient records about 3-6 months after you receive the final ImpriMed report. Once we receive the record, we input the data into the AI Models, it is not yet something that can be submitted on the Vet Portal.
Current therapy will not affect our AI predictions or immunoprofile results. However, reduction of tumor size caused by therapy may increase the likelihood of service failure due to insufficient cells. In the event of service failure, you will not be billed.
The ImpriMed Immunoprofile service includes both our Flow Cytometry and PARR reports. These comprehensive results can be used to detect the presence of lymphoma or leukemia and determine the disease subtype.
